Abstract
GABA is the major inhibitory neurotransmitter in the brain and GABA re- uptake from the synaptic cleft is one important mechanism in the regulation of GABA activity. Inhibition of the re-uptake of GABA by potent and selective inhibitors of the GABA transporter enhances GABA activity. This property can be used therapeutically in for instance epilepsy or psychiatric disorders. In this paper putative structures of the GABA transporter, its mechanism of action, the progress made in the search for its amino acids involved in the binding of substrates and the SAR of inhibitors acting at the transporter will be discussed. To date only highly selective GAT-1 inhibitors are available. These compounds are lipophilic derivatives of (R)-nipecotic acid and guvacine. The most potent inhibitors of the cloned human GAT-1 are NNC-711 (IC50 = 0.04 μM) and tiagabine (IC50 = 0.07 μM). A diheteroarylvinyloxy analogue of tiagabine, 5 times more potent than tiagabine, has been reported recently. For the GAT-2, GAT-3 and BGT-1 subtypes only compounds with a small preference for one of the subtypes have been published.
Current Medicinal Chemistry
Title: The GABA Transporter and its Inhibitors
Volume: 7 Issue: 10
Author(s): W. Soudijn and I. van Wijngaarden
Affiliation:
Abstract: GABA is the major inhibitory neurotransmitter in the brain and GABA re- uptake from the synaptic cleft is one important mechanism in the regulation of GABA activity. Inhibition of the re-uptake of GABA by potent and selective inhibitors of the GABA transporter enhances GABA activity. This property can be used therapeutically in for instance epilepsy or psychiatric disorders. In this paper putative structures of the GABA transporter, its mechanism of action, the progress made in the search for its amino acids involved in the binding of substrates and the SAR of inhibitors acting at the transporter will be discussed. To date only highly selective GAT-1 inhibitors are available. These compounds are lipophilic derivatives of (R)-nipecotic acid and guvacine. The most potent inhibitors of the cloned human GAT-1 are NNC-711 (IC50 = 0.04 μM) and tiagabine (IC50 = 0.07 μM). A diheteroarylvinyloxy analogue of tiagabine, 5 times more potent than tiagabine, has been reported recently. For the GAT-2, GAT-3 and BGT-1 subtypes only compounds with a small preference for one of the subtypes have been published.
Export Options
About this article
Cite this article as:
Soudijn W. and van Wijngaarden I., The GABA Transporter and its Inhibitors, Current Medicinal Chemistry 2000; 7 (10) . https://dx.doi.org/10.2174/0929867003374363
DOI https://dx.doi.org/10.2174/0929867003374363 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
Current Drug Targets Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology An Update of the Classical and Novel Methods Used for Measuring Fast Neurotransmitters During Normal and Brain Altered Function
Current Neuropharmacology Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye
Current Medicinal Chemistry Melatonin in Autism Spectrum Disorders
Current Clinical Pharmacology Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Application of MicroPET in Basic Epilepsy Research
Current Medical Imaging Glutathione-Related Factors and Oxidative Stress in Autism, A Review
Current Medicinal Chemistry Evaluation of Anticonvulsants for Possible Use in Neuropathic Pain
Current Medicinal Chemistry Sudden Unexplained Death in Infancy and Long QT Syndrome
Current Pediatric Reviews Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Molecular Biology of Nucleoside Transporters and their Distributions and Functions in the Brain
Current Topics in Medicinal Chemistry Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets AMPK As A Target in Rare Diseases
Current Drug Targets Anti-Vasopermeability Effects of PEDF in Retinal-Renal Disorders
Current Molecular Medicine MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design Spirooxindoles as Potential Pharmacophores
Mini-Reviews in Medicinal Chemistry Role of Noradrenergic and Orexinergic Neurons in General Anesthesia
Current Neuropharmacology Functional Characterisation of Homomeric Ionotropic Glutamate Receptors GluR1-GluR6 in a Fluorescence-Based High Throughput Screening Assay
Combinatorial Chemistry & High Throughput Screening Seizures and Antiepileptic Drugs: From Pathophysiology to Clinical Practice
Current Pharmaceutical Design